Oncgnostics
Cervical cancer diagnostics
Jena, Germany based molecular cancer diagnostics company with a focus on the development of accurate molecular diagnostic tests for use in cancer screening, therapy decision, and follow-up care.
GynTect®, oncgnostics' first product, enables reliable and fast diagnostic of cervical cancer and its preliminary stages and is ready for clinical trials.
Balmung Capital participated in the EUR 500,000 fundraising in 2016.
Summary
Investment date: 2016
Total capital commitment: EUR 500,000
Website: http://www.oncgnostics.com/
Status: current